2024 Fall Clinical Dermatology Conference Highlights

Our Annual Fall Clinical Dermatology Conference is framed to improve our attendees' value and clinical skills through a uniquely designed educational experience. Check back here as we highlight key sessions and posters during the conference!

Looking to register for Fall Clinical 2025? Click HERE

Thursday, October 24, 2024

Check Out Highlights From FC24 Below

A Roadmap for Clear Skin: Pathways to Put Acne in the Rearview Mirror

In this session, James Del Rosso, DO, and Karan Lal, DO, provided insights into management of patients with acne.

The presentation started with emphasis on patient-centered and collaborative...

Real World Approaches to Actinic Keratosis

In this session, Brian Berman, MD, PhD, and Darrell Rigel, MD, MS, provided an overview of available therapies for actinic keratoses (AKs), emphasizing combination therapies and delivering individualized...

Managing Atopic Dermatitis: 2024 & Beyond

Dr Alexandra Golant provided an overview of the evolving landscape of atopic dermatitis (AD) treatment, focusing on new insights into AD pathogenesis and therapeutic advancements that are reshaping...

Managing Facial Hyperpigmentation in All Skin Types and Colors

Andrew Alexis, MD, MPH, provides an overview of hyperpigmentation and available treatments for patients. Melasma is subcategorized into centrofacial, malar, and mandibular based on primary facial location as...

Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch

Dr Tejesh Patel presented on the pathogenesis of itch in prurigo nodularis (PN) and atopic dermatitis (AD), emphasizing the underlying mechanisms that contribute to these conditions. He explored...

Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy with Baricitinib 4-mg: Results from the BRAVE–AA1 and -AA2 Trials

Authors: Maryanne Senna, Susan Taylor, Bianca Piraccini, Jerry Shapiro, Najwa Somani, Jakub Jedynak, Samuel Ogwu, Andrew Buchanan, Brittany Craiglow, Manabu Ohyama

Baricitinib is a systemic therapy FDA approved...

Lebrikizumab confirms a consistent safety profile in adults and adolescents with moderate-to-severe atopic dermatitis: Data from 11 trials with over 3000 patient years of experience

Author: Linda Stein Gold et al.

This poster presented the most updated long-term safety data for lebrikizumab as a treatment for atopic dermatitis. The dataset included data from...

What Did 2024 Bring to The Table in Dermatology? - Part 1

In this comprehensive 5-part lecture, Linda F. Stein Gold, MD, April W. Armstrong, MD, MPH, Boni E. Elewski, MD, Dirk M. Elston, MD, and Theodore Rosen, MD, provided...

Evolving Therapies in the Treatment of Chronic Spontaneous Urticaria

Brad P. Glick, DO, MPH, David Lang, MD, and Dawn L. Merritt, DO, provided insights into chronic spontaneous urticaria (CSU). The conversation alternated between dermatology and allergist perspectives...

What’s New in the Medicine Chest - Part 2

This presentation by James Q. Del Rosso, DO, focused on recent findings in dermatologic therapies. Starting with dupilumab, a study reported that dupilumab can be an effective treatment...

Photoprotection: Where Are We Now?

Tasneem F. Mohammad, MD, delved into the current state of photoprotection, highlighting key advances and challenges in protecting the skin from harmful radiation. The presentation outlines various methods...

Treatments used among patients with psoriasis: a first look at a new patient-centered registry

Authors: Alexis Ogdle et al.

The FORWARD Psoriasis Registry was developed to collect and analyze the demographics, disease characteristics, and treatments among patients with psoriasis (PsO). The aim...

Drivers of Health in Adults with Alopecia Areata, Atopic Dermatitis, Hidradenitis Suppurativa, and Psoriasis

Authors: Candrice R. Heath et al.

Social determinants of health, including socioeconomic and environmental factors, play a critical role in influencing health outcomes. In dermatology, understanding these determinants...

What Did 2024 Bring To The Table In Dermatology? - Part 2

This 4-part lecture series built on “What Did 2024 Bring to the Table in Dermatology – Part 1” and provided even more updates on dermatology advancements. Dr Lisa...

Topical Therapy Forum

The "Topical Therapy Forum" lecture series presented an in-depth look at advancements in topical treatments across several dermatologic conditions, with each expert delving into the latest innovations and...

The Comorbidities of Psoriasis: What Clinicians Need to Know to Optimize Care

The presentation on the comorbidities of psoriasis, led by Drs Bruce E. Strober, Joel M. Gelfand, and Karan Lal, highlighted the significant health risks associated with psoriasis. The...

JAK to the Future: Advancing Alopecia Areata Care with Oral JAK Inhibitors

This session explores the latest clinical evidence on the efficacy and safety of oral JAK inhibitors for managing alopecia areata (AA), including criteria for patient selection, dose adjustment...

Visible cohort B: Scalp clearance through week 48 with guselkumab in participants with moderate-to-severe scalp psoriasis across all skin tones

Authors: A. McMichael et al.

This poster presents data from the Phase 3b VISIBLE study, a multicenter, randomized, double-blind, placebo-controlled trial evaluating guselkumab (GUS) in participants with moderate-to-severe...

Sustained improvements in psoriasis area and severity index and in percent body surface area of psoriasis with JNJ-77242113 in patients with moderate-to-severe plaque psoriasis: Treat-to-target analyses in the FRONTIER 1 & 2 studies

Authors: Kim A Papp et al.

The poster presents findings from the Phase 2 FRONTIER 1 and long-term extension FRONTIER 2 studies, evaluating the efficacy and safety of...

What’s New in JAMA Derm?

Dr April W. Armstrong’s presentation highlighted a series of impactful recent studies, covering a broad range of dermatologic conditions and treatments, published in JAMA Dermatology. She begins...

What’s New in JAAD?

Dr Dirk Elston presented a comprehensive review of the top JAAD articles and findings from 2024. Dr Elston truly highlighted the major impact of JAAD with a presentation...

What’s New in SKIN?

Dr Roger Ceilley provided a comprehensive overview of the past year for SKIN: The Journal of Cutaneous Medicine, highlighting the journal’s rapid growth and valuable contributions to...

What’s New in Dermatologic Surgery?

Dr Marc D. Brown’s presentation provided a detailed overview of recent studies shaping dermatologic surgery practices published in Dermatologic Surgery. One key topic addressed in the journal...

Deucravacitinib in plaque psoriasis: laboratory parameters through 4 years of treatment in the phase 3 POETYK PSO-1, PSO-2 and LTE trials

Author: Neil J. Korman et al.

Deucravacitinib, an oral TYK2 inhibitor, is FDA approved for the systemic treatment of moderate-to-severe plaque psoriasis. This poster presents updated four-year data...

Decruavacitinib in plaque psoriasis: 4-year safety and efficacy results from phase 3 POETYK PSO-1 PSO-2, and LTE trials

Author: April W. Armstrong et al.

Deucravacitinib, an oral TYK2 inhibitor, is FDA approved for the systemic treatment of moderate-to-severe plaque psoriasis. This poster presents updated four-year safety...

Meet the Author

Untitled design (1).png

Brooke Bartley, MD
Internal Medicine Preliminary Resident
Texas Health Presbyterian Dallas